Status
Conditions
Treatments
About
The objective of this study is to demonstrate initial safety and functionality of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with paroxysmal atrial fibrillation.
Full description
This study is a prospective, non-randomized, open labelled, single-arm first-in-human (FIH) feasibility study to evaluate the initial clinical safety and device performance of the nano-PFA 360 Catheter Endocardial Ablation System for the treatment of paroxysmal atrial fibrillation. Enrolled subjects will be followed for up to 12 months post-nano PFA 360 Catheter Ablation. All subjects will undergo an electroanatomical mapping procedure post-ablation to evaluate immediate pulmonary vein isolation (PVI) and at 3 months post-index procedure to assess electrical isolation of the pulmonary veins.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or CRT) or left atrial appendage device
Subject has a prosthetic heart valve
AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
AF episodes lasting > 7 days
Previous ablation for AF
Subjects on amiodarone at any time during the past 3 months prior to enrollment
Prior history of pericarditis or pericarditis within 3 months based on the TTE examination
Prior history of rheumatic fever
Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, atrial septal defect (ASD) closure, left atrial appendage occlusion)
History of severe chronic gastrointestinal problems involving the esophagus, stomach and/or untreated acid reflux
History of abnormal bleeding and/or clotting disorder
Contraindication to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as Warfarin)
Active malignancy or history of treated cancer within 24 months of enrollment
Clinically significant infection or sepsis on the day of index procedure with either fever, leukocytosis or requiring intravenous antibiotics
History of stroke or TIA within prior 6 months, or any prior intracranial hemorrhage or permanent neurological deficit
New York Heart Association (NYHA) class IIIb or IV congestive heart failure and/or any heart failure hospitalization within 3 months prior to enrollment
Body mass index > 35 kg/m2
Estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or has ever received hemodialysis
History of untreated and serious hypotension, bradycardia or chronotropic incompetence
Any of the following within 3 months of enrollment:
Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
History of pulmonary hypertension with pulmonary systolic artery pressure >50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease
Subjects with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder)
Life expectancy less than one year
Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
Females of childbearing potential who are nursing, pregnant, or planning to become pregnant during the study period
Other criteria, which the Investigator determines would make the patient unsuitable to participate (e.g. uncontrolled drug and/or alcohol addiction, congenital disease, fragility)
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Central trial contact
Aleksandra Kurek; William A. Knape
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal